.
MergerLinks Header Logo

New Deal


Announced

KKR to acquire a 54% stake in JB Chemicals & Pharmaceuticals for $500m.

Financials

Edit Data
Transaction Value£401m
Consideration TypeCash
Capital Owned-
Capital Bid For54%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pending

Private Equity

pharmaceuticals

Acquisition

Friendly

India

biopharmaceuticals

Majority

Single Bidder

Pharmaceuticals

Public

Cross Border

Synopsis

Edit

KKR & Co agreed to acquire a 54% stake in JB Chemicals & Pharmaceuticals, an Indian pharmaceutical company specializing in branded formulations, for $500m. The transaction is subject to regulatory and other customary approvals. “For more than four decades, J.B. Chemicals’ mission has been to deliver affordable, high-quality pharmaceutical products that improve the lives of individuals living in India and around the world. We are thrilled that KKR – with its deep knowledge of the pharmaceutical industry and experience in investing in the sector, as well as its extensive investments in India – will take our mission forward and build on the foundation of core values that our family has instilled in this company. This will also create growth opportunities for our people to progress,” J.B. Mody, Founder, Chairman and Managing Director of JB Chemicals. On August 26, 2021, CCI approved the transaction after detailed rounds of queries.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US